Semaglutide (Wegovy) is also used to treat metabolic dysfunction-associated steatohepatitis (MASH), without cirrhosis of the liver
signal increased enforcement and a push back toward branded medications
Key gaps include immune response, metabolic effects, repeated-exposure risks, tissue selectivity, fertility and pregnancy safety, cancer-related concerns, and interactions with other anabolic or endocrine agents [15] [20]
The mechanism seems to be independent of the catalytic activity, since these effects were not mimicked by systemic DPP-4 inhibition (73, 82), and it was suggested that soluble DPP-4 interacted with caveolin-1 on adipose tissue macrophages, the down-stream effects of which combined with actions of other pro-inflammatory molecules such as factor Xa, to lead to activation of the inflammatory signaling pathway (83) (Figure 3)